CVS Caremark, Sharecare launch digital pharmacy savings card
Digital health company Sharecare is partnering with CVS Caremark, the pharmacy benefit management business of CVS Health, to launch Sharecare Rx, a digital pharmacy savings card to help people who are uninsured or may lack sufficient drug coverage save money on their prescription medications.
Sharecare Rx, available exclusively through the free Sharecare app, will offer access to discounts on drugs within the CVS Caremark national pharmacy network.
In addition to helping people find the best price on both generic and branded prescription medications, Sharecare enables people to access information and tools to help them overcome some of the most significant barriers to medication adherence besides cost, such as convenience and education, the company said.
“Whether treating strep throat or managing a chronic condition, the modern healthcare experience cannot be comprehensive without medications, yet the burdens of choice and cost placed on people can be overwhelming,” Sharecare chairman and CEO Jeff Arnold said. “By partnering with CVS Caremark to build Sharecare Rx into our platform, we are removing barriers to empower consumers to truly manage all their health in one place. We are also actively working with our health plan and employer partners to integrate their formulary coverage and pricing into Sharecare so their members can seamlessly access their prescription benefits, as well as information and tools to help them adhere to a healthier regimen.”
Accepted at the more than 68,000 pharmacies in the CVS Caremark network — from such large national retail pharmacies as CVS, Walgreens and Walmart to locally owned community pharmacies — Sharecare Rx enables people to search for a specific medication, filtering results by drug price, pharmacy distance, and availability of 24-hour and drive-thru pharmacy services.
Once someone selects their preferred drug result, they can redeem the discounted price by presenting the Sharecare Rx card — found in the Sharecare app under You > Wallet — during checkout at a participating network pharmacy.
Sharecare Rx leverages CVS Caremark’s scale and expertise in negotiating lower medication prices with pharmaceutical manufacturers to bring Sharecare users affordable prices.
“As the high cost of prescription drugs continues to present a challenge for millions of Americans, we are committed to finding ways to help uninsured or underinsured populations access affordable medications,” CVS Caremark president Derica Rice said. “By leveraging our size, scale, expertise and access, this new program with Sharecare will help Americans, who lack prescription drug coverage, find lower-cost drug options at convenient pharmacy locations that encompass large chains and locally owned independent pharmacies.”
Astellas launches Xospata
Astellas Pharma is offering Xospata (gilteritinib) for the treatment of adult patients who have relapsed or treatment resistant acute myeloid leukemia with a FLT3 mutation detected by an FDA-approved test.
Acute myeloid leukemia is a cancer that impacts the blood and bone marrow, and its incidence increases with age.
Xospata, an oral monotherapy, is the first and only FLT3-targeting agent approved by the FDA for the treatment of relapsed or refractory FLT3 mutation positive (FLT3mut+) acute myeloid leukemia, according to the company.
“Astellas aims to pursue cutting-edge science that provides value to patients,” Astellas’ senior vice president of oncology business unit Mark Reisenauer said. “Xospata is an excellent example of how we are continuing to advance on this promise to patients.”
Gilteritinib was discovered through a research collaboration with Kotobuki Pharmaceutical. Astellas has exclusive global rights to develop, manufacture and commercialize gilteritinib.
No comments found
Mayne Pharma gets FDA nod for Tolsura
Mayne Pharma Group has received clearance from the Food and Drug Administration for Tolsura (SUBA-itraconazole, 65-mg capsules).
Tolsura is a new formulation of itraconazole indicated for the treatment of certain systemic fungal infections in adult patients.
The product is indicated for the treatment of blastomycosis (pulmonary and extrapulmonary), histoplasmosis (including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis) and aspergillosis (pulmonary and extrapulmonary, in patients who are intolerant of or who are resistant to amphotericin B therapy.
These serious infections most commonly occur in vulnerable or immunocompromised patients, for example, those with a history of cancer, transplants (solid organ or bone marrow), HIV/AIDS, or chronic rheumatic disorders, and are often associated with high mortality rates or long-term health issues.
“We are very pleased to have received FDA approval of this patented formulation of itraconazole which incorporates Mayne Pharma’s proprietary SUBA technology to improve the bioavailability of poorly soluble drugs. Reformulation of existing drugs plays an important role in improving patient compliance and clinical outcomes. We are proud to offer a new treatment option for patients with these life-threatening infections,”Mayne Pharma’s CEO Scott Richards said.
Anti-fungal triazole has a market value of $600 million, according to IQVIA data.
No comments found